Bank of America reports 5.8% stake in Travere

Rhea-AI Filing Summary

Bank of America Corporation, through certain wholly owned subsidiaries, reported beneficial ownership of 5,439,155 shares of Travere Therapeutics, Inc. common stock on a Schedule 13G. This represented 5.8% of the class, based on 94,174,767 shares outstanding as of June 30, 2026, as reported by Travere in a Form 10-Q filed August 4, 2026.

Bank of America reported no sole voting or dispositive power over Travere shares. It reported shared voting power over 5,103,492 shares and shared dispositive power over 5,325,237 shares, reflecting positions held across subsidiaries including BofA Securities, Inc., Bank of America N.A., Merrill Lynch International, Merrill Lynch Pierce Fenner & Smith, Inc., and U.S. Trust Co of Delaware.

Key Figures

Beneficially owned shares: 5,439,155 shares Percent of class: 5.8% Shares outstanding baseline: 94,174,767 shares +5 more

8 metrics

Beneficially owned shares 5,439,155 shares Travere Therapeutics common stock reported by Bank of America Corporation

Percent of class 5.8% Ownership percentage of Travere common stock based on shares outstanding

Shares outstanding baseline 94,174,767 shares Travere shares outstanding as of June 30, 2026 from Form 10-Q

Shared voting power 5,103,492 shares Travere shares over which Bank of America has shared voting power

Shared dispositive power 5,325,237 shares Travere shares over which Bank of America has shared dispositive power

Sole voting power 0 shares Travere shares over which Bank of America has sole voting authority

Sole dispositive power 0 shares Travere shares over which Bank of America has sole dispositive authority

Reporting date signature 08/12/2026 Date the Schedule 13G was signed by an authorized signatory

Key Terms

beneficial ownership, sole voting power, shared dispositive power, Schedule 13G, +1 more

5 terms

beneficial ownership financial

"The beneficial ownership calculation relies on the 94,174,767 outstanding shares"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

sole voting power financial

"Sole Voting Power 0.00 6 | Shared Voting Power 5,103,492.00"

Sole voting power is the exclusive right to cast votes attached to a shareholder’s stock without needing approval from anyone else. Like holding the only remote control for a TV, it lets that holder decide corporate matters such as board members, mergers, and policy changes, making it important to investors because it concentrates control and can strongly influence a company’s strategy and the value of its shares.

shared dispositive power financial

"Shared Dispositive Power 5,325,237.00"

Schedule 13G regulatory

"If a parent holding company has filed this schedule, pursuant to (ii)(G)"

A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.

parent holding company financial

"If a parent holding company has filed this schedule, pursuant to (ii)(G)"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What percentage of Travere Therapeutics (TVTX) shares does Bank of America report owning?

Bank of America reports beneficial ownership of 5.8% of Travere Therapeutics’ common stock. This is based on 94,174,767 shares outstanding as of June 30, 2026, as disclosed by Travere in its Form 10-Q.

How many Travere Therapeutics (TVTX) shares does Bank of America beneficially own?

Bank of America reports 5,439,155 Travere Therapeutics common shares as beneficially owned. This position underpins its 5.8% ownership stake, calculated using Travere’s reported 94,174,767 shares outstanding as of June 30, 2026.

What voting power does Bank of America have over Travere Therapeutics (TVTX) shares?

Bank of America reports 0 shares with sole voting power and 5,103,492 shares with shared voting power in Travere Therapeutics. All reported voting authority is therefore held on a shared basis across its subsidiaries.

What dispositive power does Bank of America report for its Travere Therapeutics (TVTX) stake?

Bank of America reports 0 shares with sole dispositive power and 5,325,237 shares with shared dispositive power. These figures indicate its ability, shared with affiliates, to direct the disposition of Travere shares held through its subsidiaries.

Which Bank of America subsidiaries hold Travere Therapeutics (TVTX) shares?

The filing states it is made on behalf of Bank of America Corporation and subsidiaries including BofA Securities, Inc., Bank of America N.A., Merrill Lynch International, Merrill Lynch Pierce Fenner & Smith, Inc., and U.S. Trust Co of Delaware.

How was Bank of America’s 5.8% ownership in Travere Therapeutics (TVTX) calculated?

The 5.8% ownership figure uses 94,174,767 Travere shares outstanding, as disclosed in Travere’s Form 10-Q filed August 4, 2026 and stated as outstanding as of June 30, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 08/12/2026 - 01:28 PM EDT Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Travere Therapeutics, Inc.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

89422G107

(CUSIP Number)

06/30/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 89422G107

1

Names of Reporting Persons

BANK OF AMERICA CORP /DE/

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 5,103,492.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 5,325,237.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

5,439,155.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.8 %

12

Type of Reporting Person (See Instructions)

HC

Comment for Type of Reporting Person: The beneficial ownership calculation relies on the 94,174,767 outstanding shares disclosed in the Form 10-Q by the issuer on August 4, 2026, which reports share totals as of June 30, 2026.

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Travere Therapeutics, Inc.
(b)	Address of issuer's principal executive offices: 3611 VALLEY CENTRE DR, SUITE 300, SAN DIEGO, CALIFORNIA, 92130.
Item 2.
(a)	Name of person filing: BANK OF AMERICA CORP /DE/
(b)	Address or principal business office or, if none, residence: 100 N TRYON ST CHARLOTTE, NC 28255
(c)	Citizenship: Delaware
(d)	Title of class of securities: Common Stock
(e)	CUSIP Number(s): 89422G107
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 5,439,155.00
(b)	Percent of class: 5.8%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 0.00
	(ii) Shared power to vote or to direct the vote: 5,103,492.00
	(iii) Sole power to dispose or to direct the disposition of: 0.00
	(iv) Shared power to dispose or to direct the disposition of: 5,325,237.00
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary. This statement on Schedule 13G is being filed by Bank of America Corporation on behalf of itself and its wholly owned subsidiaries BofA Securities, Inc., a broker dealer registered under section 15 of the Act (15 U.S.C. 78o); Bank of America N.A., a bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c); Merrill Lynch International, a non-U.S. institution in accordance with section 240.13d-1(b)(1)(ii)(J); Merrill Lynch Pierce Fenner & Smith, Inc., a broker dealer registered under section 15 of the Act (15 U.S.C. 78o); and U.S. Trust Co of Delaware, a corporation which holding does not exceed one percent of the reported securities.
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

BANK OF AMERICA CORP /DE/

Signature:	/s/ Monica Yako
Name/Title:	Authorized Signatory
Date:	08/12/2026